期刊
HEMATOLOGY REPORTS
卷 15, 期 3, 页码 440-447出版社
MDPI
DOI: 10.3390/hematolrep15030045
关键词
Brugada syndrome; acute promyelocytic leukemia; arsenic; all-trans-retinoic acid; sudden death
类别
This article presents a case of a BrS patient diagnosed with low-risk APL and treated with ATRA and ATO therapy. The article highlights the challenges encountered by clinicians in the diagnosis and treatment choice for these patients.
Acute promyelocytic leukemia (APL) is a rare and aggressive form of acute myeloid leukemia (AML). Instead of cytotoxic chemotherapy, a combination of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) represents front-line therapy in low-risk patients. However, the therapeutic approach could be challenging in the case of a concomitant diagnosis of Brugada syndrome (BrS), a genetic disease characterized by an increased risk of arrhythmias and sudden cardiac death. Here, we present the case of a BrS patient who has been diagnosed with low-risk APL and treated with ATRA and ATO without observing arrhythmic events. In particular, we highlight the difficulties encountered by clinicians during the diagnostic work-up and the choice of the best treatment for these patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据